INTRODUCTION
The ubiquitin-proteasome system (UPS) controls the stability, interactions, and localization of many thousands of proteins across virtually all cellular processes. Ubiquitin conjugation to substrate lysine residues is catalyzed by a conserved enzymatic cascade: an E1 enzyme activates ubiquitin as a thioester in an ATP-dependent manner and transfers the activated ubiquitin to the catalytic cysteine residue of an E2, which then interacts with an E3 enzyme to conjugate ubiquitin as an isopeptide bond onto the substrate (Nalepa et al., 2006) . E3 enzymes, also referred to as ubiquitin ligases, confer substrate specificity via specific protein interaction domains and fall into two broad classes: the HECT domain class forms a catalytic ubiquitin thioester intermediate, whereas the RING domain class juxtaposes the charged E2 next to the substrate (Pickart, 2001 ). The human genome encodes two E1 enzymes, at least 38 E2 enzymes, and more than 600 distinct E3 enzymes, each of which has the potential to recognize multiple substrates (Li et al., 2008) .
The largest family of E3 enzymes, the cullin-RING ligases (CRLs), were first discovered as the multisubunit Skp1-Cdc53/ Cullin-F box protein (SCF) ubiquitin ligases. SCF complexes contain the core subunits Skp1, Cdc53/Cul1, and Rbx1/Roc1/ Hrt1 and a cohort of adaptor subunits called F box proteins that recruit specific substrates to the core complex, often in a phosphorylation-dependent manner (Bai et al., 1996; Feldman et al., 1997; Patton et al., 1998; Petroski and Deshaies, 2005; Skowyra et al., 1997; Willems et al., 1996) . As for all RING domain E3 enzymes, SCF complexes capture substrates for E2-mediated ubiquitination but do not possess catalytic activity per se (Petroski and Deshaies, 2005) . SCF-like complexes built on a similar adaptor-cullin-RING architecture include the anaphase promoting complex/cyclosome and the Cul2-, Cul3-, Cul4A-, Cul5-, and Cul6-based ubiquitin ligases. The CRL class thus has the capacity to target many hundreds, if not thousands, of proteins for degradation (Petroski and Deshaies, 2005; Yen and Elledge, 2008) . A crucial requisite for CRL activity is covalent modification of the cullin subunit by a ubiquitin-like modifier called Nedd8 (Petroski and Deshaies, 2005) . Nedd8 modification dramatically increases the conformational flexibility of the Rbx1 subunit to allow the docked E2 to efficiently access substrate lysine residues (Duda et al., 2008) .
E2 enzyme properties govern both the type of ubiquitin linkage and the extent of ubiquitin modification (Wenzel et al., 2010; Ye and Rape, 2009) . Monoubiquitination typically alters protein interactions in vesicle trafficking, DNA repair, and other processes, whereas polyubiquitination usually leads to substrate recognition and degradation by the 26S proteasome (Ravid and Hochstrasser, 2008) . Different E2 enzymes can build polymers with different ubiquitin linkages, which can also lead to different fates. Multiple mechanisms-including E3 multimerization and conformational changes, ubiquitin placement and chain assembly on the E2, and E2-specific initiation versus elongation steps-all serve to coordinate E2 loading and unloading cycles with substrate-E3 interactions (Ye and Rape, 2009) . Notably, the primary E2 for the CRL class, Cdc34, acts in a highly processive fashion due to the rapid exchange of its unique acidic C-terminal tail with the cullin subunit Pierce et al., 2009) .
As the UPS is frequently perturbed in cancer, neurological, and immunological disorders and infectious disease, the modulation of UPS enzymatic activities is of intense therapeutic interest (Cohen and Tcherpakov, 2010; Nalepa et al., 2006) . In particular, the F box proteins Skp2 and b-TrCP are often overexpressed in primary cancers, whereas Fbw7 is a frequent mutated tumor suppressor (Frescas and Pagano, 2008; Welcker and Clurman, 2008) . Phosphorylation of the cyclin-dependent kinase (CDK) inhibitor p27
Kip1 by cyclin E-Cdk2 drives its recognition and ubiquitination by SCF Skp2 , thereby enabling cell-cycle progression through G1 phase (Frescas and Pagano, 2008) . As the SKP2 locus is often amplified and overexpressed in human cancer, SCF Skp2 is a candidate target for therapeutic intervention (Nalepa et al., 2006) . Human CRLs have been subjected to smallmolecule screens to identify inhibitors of different catalytic and substrate recognition steps (Aghajan et al., 2010; Chen et al., 2008; Orlicky et al., 2010; Soucy et al., 2009 ). Here, we report a small-molecule screen for inhibitors of SCF Skp2 -dependent ubiquitination of p27
Kip1 and identify a novel allosteric inhibitor of the human Cdc34 enzyme.
RESULTS
A Small-Molecule Screen against SCF Skp2 Identifies a hCdc34 Inhibitor To screen for small-molecule inhibitors of all key steps in an SCFcatalyzed ubiquitination reaction, we developed a HTP-compatible assay based on ubiquitination of the human CDK inhibitor p27 Kip1 by the SCF Skp2 E3 complex (Chen et al., 2008) . This recombinant assay system contained biotinylated-ubiquitin, the E1 enzyme Uba1, the E2 enzyme hCdc34, the SCF Skp2 complex, Cks1, and p27 Kip1 that was phosphorylated by cyclin E-Cdk2. Ubiquitination of p27 Kip1 was assessed by capture onto an anti-p27
Kip1 antibody affinity surface and quantitative detection with a europium-streptavidin conjugate. In an extensive small-molecule campaign, we identified a compound designated CC0651 that potently (IC 50 = 1.72 mM) inhibited the ubiquitination of p27 , as confirmed by dose-response analysis ( Figure 1A ). CC0651 corresponds to (2R,3S,4S)-5-(3 0 ,5 0 -dichlorobiphenyl-4-yl)-2,3-dihydroxy-4-(2-methoxyacetamido) pentanoic acid and has a molecular mass of 442.3 g/mol ( Figure 1B ). The calculated Log P and Log D values for CC0651 were 2.46 and 0.985, with an aqueous solubility of 1 mg/ml at pH 7.4. CC0651 contains three chiral centers and was resynthesized for use in all subsequent assays in enantiomerically pure form.
To narrow down the potential target(s) for CC0651 in the multicomponent SCF Skp2 reaction, we tested its activity against other E3 enzymes and substrates. CC0651 inhibited the activity of SCF b-TrCP1 toward a phospho-IkBa peptide and of SCF Fbw7 toward phospho-cyclin E ( Figure 1C ), suggesting that CC0651 was not selective for different SCF complexes. CC0651 had no effect on activity of the human HECT domain enzyme SMURF2, the Shigella IpaH enzyme SspH1, or the human RING domain enzyme Rnf168 ( Figure S1A -S1C available online). Because ubiquitin and E1 enzyme were common to all five of the in vitro reactions tested, we excluded both of these components as targets of CC0651. The remaining possible targets for CC0651 were thus the E2 enzyme hCdc34 and the core SCF subunits Skp1, Cul1, and Rbx1. We used an in vitro reaction reconstituted from budding yeast Cdc34 and SCF Cdc4 to delineate CC0651 mechanism of action (Orlicky et al., 2003) . CC0651 had no effect on ubiquitination of the yeast CDK inhibitor Sic1 in the yeast Cdc34-SCF Cdc4 reaction ( Figure 1D ). However, substitution of yeast Cdc34 with hCdc34 in this reaction caused CC0651 to robustly inhibit Sic1 ubiquitination ( Figure 1D ). Thermal denaturation assays suggested that CC0651 specifically bound to hCdc34, but not to other control proteins ( Figure S2A-S2F ). These biochemical and biophysical data strongly suggested that the target of CC0651 is hCdc34.
Structural Analysis of hCdc34 Alone and in Complex with CC0651
To investigate the mechanism whereby CC0651 inhibits hCdc34, we determined the structure of hCdc34 alone and in complex with CC0651. Although many E2 enzyme structures are known (Burroughs et al., 2008; Wenzel et al., 2010; Ye and Rape, 2009) , the structure of Cdc34 has not been solved previously. hCdc34 possesses a conserved acidic C-terminal extension of 54 residues that is critical for its efficient interaction with Cul1 but is not required for catalytic activity per se . A C-terminal deletion construct that lacks the acidic tail, denoted hCdc34 D184 ( Figure S3 ), yielded crystals suitable for structure determination by molecular replacement using UbcH7 coordinates (PDB 1FBV) as a search model. Data collection and refinement statistics for the apo-and inhibitor-bound hCdc34 D184 structures, resolved at 2.4 Å and 2.3 Å resolution, respectively, are summarized in Table S1 . The structure of hCdc34 D184 consists of a four-stranded antiparallel b sheet, denoted strands b1 to b4, flanked by four a helices, denoted helices a1 to a4 (Figure 2A ). This structure is similar to that of all other E2 structures solved to date (Burroughs et al., 2008) . The two long connector segments that link strand b4 with helix a2 and helix a2 with helix a3 comprise the active site region of the E2 enzyme. The catalytic cysteine residue Cys93 lies within the b4-a2 connector and immediately precedes the structurally conserved 3 10 helix. The sequence that links the 3 10 helix to helix a2 of hCdc34 is 13 residues longer than in most other E2s; 15 residues of this linker sequence are disordered in the hCdc34 D184 structure. We note that, in the apo hCdc34 D184 structure, the catalytic cysteine forms a disulfide bridge with a symmetry-related molecule in the crystal. This artificial crosslink appears to distort the orientation of the 3 10 helix relative to other E2 structures. For this reason, in subsequent analyses, we used the structures of UbcH5b or Ubc9 as alternate reference points for active apo-E2 structures (Ozkan et al., 2005; Yunus and Lima, 2006) . The structure of the CC0651-hCdc34 D184 complex was solved by molecular replacement using the apo-hCdc34 D184 coordinates as a search model. This analysis revealed unambiguous electron density for CC0651 at a site 19 Å distal from the active site residue Cys93 ( Figure 2B and Figure S4A ). The asymmetric unit of this crystal form contained four molecules of hCdc34 D184 , with each bound to similarly oriented CC0651 molecules ( Figure S4B ). Two of the hCdc34 D184 molecules (chains C and D) again formed a disulfide bridge linked through the active site cysteine. As this covalent linkage is unlikely to reflect See Figure S1 and Figure S2 for associated data. a biologically relevant conformation, we focused our analysis on the two noncovalently linked hCdc34 D184 molecules (chains A and B). CC0651 bound to a pocket formed by the a1-b1 linker, the C-terminal end of helix a2, the b2-b3 linker, the C-terminal end of helix a3, and the a3-a4 linker ( Figures 2B and 2C ). The 354 Å 2 contact surface between CC0651 and hCdc34 D184 was dominated by hydrophobic interactions. The biphenyl ring system of CC0651 embedded within a hydrophobic pocket lined by Phe28, Ile45, Pro48, Tyr53, Phe58, Phe77, Met81, Ile128, Leu131, and Ile165. The aliphatic portion of CC0651 engaged a mixed polar and hydrophobic environment created by Asn50, Tyr52, Pro134, Tyr148, Trp151, Tyr161, and Thr162. Despite the potential for hydrogen bond interactions, only one such interaction was observed, namely between the backbone amide group of Tyr52 with the acetamido carbonyl group of CC0651. Consistent with this dearth of polar interactions, the carboxylic acid group of CC0651 sampled alternate binding conformations in the four copies of hCdc34 D184 within the crystal asymmetric unit ( Figure S4B ).
Mutational Analysis of the CC0651 Binding Pocket
Sequence comparisons revealed that many of the residues that line the inhibitor binding pocket are unique to hCdc34 and its close homolog Ube2R2 ( Figure S3 ). These differences may account for the observed inhibitory properties of CC0651 toward hCdc34, but not UbcH5, UbcH7, or Ubc13/Uev1a. To validate the CC0651 binding mode observed in the crystal structure and to probe the determinants of inhibitor selectivity, we mutated critical but nonconserved binding pocket residues and examined the effect of these mutations in the hCdc34-yeast SCF Cdc4 assay. Tyr52 occupies a highly variable position in hCdc34 yet appeared vital for organizing the b2-b3 loop that forms the only strong hydrogen bond with CC0651. This position is occupied by Tyr or Phe only in the two human E2 enzymes Ube2F and Ube2M/Ubc12, respectively. Ile128 and Asn132 both lie in helix a2 and interact with the biphenyl system of CC0651; these positions are also highly variable in different E2 enzymes. As predicted from the CC0651-hCdc34 structure, mutation of each of the contact residues attenuated the inhibitory effect of CC0651 on hCdc34 without compromising enzymatic activity toward Sic1 ( Figure 2D ). As no other human E2s possess each of the Tyr, Ile, and Asp contact residues, CC0651 is likely to selectively inhibit hCdc34. Indeed, Ube2R2 lacks only the Tyr contact residue compared to hCdc34 and yet is fully resistant to CC0651 in the surrogate Sic1 ubiquitination assay ( Figure 2E ).
Structure-Activity Relationships of CC0651 Analogs
We synthesized 12 analogs of CC0651 and compared their ability to inhibit hCdc34-dependent Sic1 ubiquitination in vitro (Figures 3A and 3B) and also the activity of SCF Skp2 , SCF bTrCP , and SCF Fbw7 (see Figure S5 and Figure S6 for dose-response profiles). Increasing the separation of the two phenyl ring systems by insertion of an intervening amino group (CC9833) resulted in the complete loss of inhibitory activity. Similarly, elimination or substitution of the entire polar pentanoic acid-acetoamido-methoxy system (CC9430, CC9504, CC9535, and CC9566) resulted in a complete loss of inhibitory function. Thus, both the hydrophobic and polar elements of CC0651 are essential for hCdc34 inhibition.
We then generated more subtle substitutions in the polar half of CC0651. Analogs that substituted or blocked the carboxylate moiety of the pentanoic acid group with a hydroxyl moiety (CC9933), an aliphatic amine (CC9807), a five-chain ether moiety (CC7094), or methoxy ester linkage (CC8993) retained inhibitory activity with descending potency. Activity was weakly affected by modification of the two hydroxyl groups by reduction (CC0040) or by cyclization (CC9653); the reduced analog simplifies the synthetic route by eliminating two of three chiral centers in CC0651. Finally, substitution of the methoxy group with a benzyl group in the reduced analog (CC9652) demonstrated that the ether group was not essential for activity. Though we did not target the acetamido carbonyl group of CC0651 for modification, based on the polar region analogs, we predict that this moiety is important for function. None of the CC0651 analogs exhibited significant activity against Ube2R2, demonstrating that E2 selectivity was retained across the series (Figure S5 ). These in vitro SAR results delineate the key features of CC0651 and provide a basis for further compound optimization.
Activity of CC0651 Analogs In Vivo
We then determined whether CC0651 or any of its analogs had biological activity in human cells. Antisense suppression of hCdc34 in human diploid fibroblasts is known to elevate p27 Kip1 levels (Butz et al., 2005) , and consistently we found that shRNA-mediated hCdc34 silencing caused p27 Kip1 accumulation and inhibition of cell proliferation in both the PC-3 prostate and HCT 116 colorectal cancer cell lines, without affecting p27 Kip1 mRNA levels ( Figures S7A-S7C ). Specific knockdown of either hCdc34 or Ube2R2 caused equivalent effects on p27 Kip1 and proliferation, suggesting that the two E2 isoforms function in a partially nonredundant manner. We then tested CC0651 and its analogs for effects on PC-3 cells. The CC7094 analog, which has modest activity in vitro, and an ester analog See Figure S3 and Figure S4 for associated data.
of CC0651 (CC8993) inhibited cell proliferation with an IC 50 of 20 mM ( Figure 4A ) and caused a progressive increase in p27 Kip1 levels ( Figure 4B ), again without affecting p27
Kip1 mRNA ( Figure S7D ). Consistently, upon exit from quiescence in the presence of inhibitor analogs, p27 Kip1 and cyclin E levels were also elevated ( Figure 4C and Figures S7E and S7F ). In comparison, the potent Nedd8-activating enzyme inhibitor MLN4924, which abrogates all SCF and CRL ubiquitin ligase activity (Soucy et al., 2009) , caused more pronounced p27 Kip1 and cyclin E accumulation in this assay. The moderate accumulation of p27 Kip1 in these assays probably reflects the limited bioavailability of the first-generation CC0651 derivatives, as well as parallel p27 Kip1 degradation pathways in vivo (Kamura et al., 2004) . To further validate that the effects of the inhibitor were mediated through hCdc34, we added the ester analog CC8993 to PC-3 cells that had been infected with an shRNA against hCdc34. The prior reduction of hCdc34 expression largely abrogated the effect of the inhibitor on cell proliferation ( Figure 4D ). In a parallel assay for target specificity, we observed that treatment of cells with the ester analog caused accumulation of a covalent hCdc34-ubiquitin conjugate ( Figure 4E ), which is a known byproduct of Cdc34-dependent catalysis (Scaglione . Asterisk denotes analogs that retain biochemical activity. See Figure S5 and Figure S6 for dose-response profiles of all analogs, including the methyl ester derivative CC8993. et al., 2007) . The appearance of the conjugate was not merely a consequence of SCF pathway inhibition because it did not arise upon MLN4924 treatment, and consistently, CC0651 caused production of the hCdc34-ubiquitin conjugate during in vitro reactions (see below). Collectively, these data suggest that CC0651 and some of its analogs are able to specifically interdict hCdc34 function in vivo, with concomitant effects on p27
Kip1 accumulation and cell proliferation.
Induction of the CC0651 Binding Pocket Causes LargeScale Structural Rearrangements
Comparison of the apo-and CC0651-bound structures of hCdc34, which have an RMSD of 0.94 Å over 142 residues, revealed that the CC0651-binding pocket is only partially preformed in the absence of the inhibitor ( Figure 5A ). We thus considered the possibility that long-range structural distortions resulting from induction of the binding pocket might explain abundance determined by immunoblot. (C) G0/G1-synchronized PC-3 cultures were treated with DMSO or CC0651, CC7094, or CC8993 (all at 30 mM) or MLN4924 (4 mM) for 16 hr, followed by detection of p27 Kip1 and cyclin E by immunoblot.
(D) PC-3 cultures were infected with lentiviruses encoding control nontarget (NT) or hCdc34-specific shRNA 24 hr prior to treatment with CC8993 for 4 days and proliferation assessed by MTT assay. Values correspond to mean ± SEM of six determinations. (E) Posttranslational modification of hCdc34 in G0/G1-synchronized PC-3 or HCT 116 cultures treated with DMSO, CC7094 (30 mM) or CC8993 (30 mM), or MLN4924 (4 mM) and analyzed by anti-Cdc34 immunoblot under reducing conditions. See Figure S7 for associated data.
the inhibitory effects of CC0651. Preformed cavities that accommodate the moieties at each end of CC0651, namely for the chlorine atom of the first phenyl ring system and the methoxyl aliphatic chain, are apparent in the apo-hCdc34 structure (Figure 5A ). In contrast, the central region of the binding pocket that accommodates the bulky biphenyl ring system is completely occluded in the absence of CC0651. Induction of the binding pocket arises from the outward displacement of helix a2 by 2.1 Å and of the b2-b3-connecting segment by 1.7 Å ( Figure 5A ). Figure 5 . Influence of CC0651 Interactions on hCdc34 Structure (A) Surface representation (left) of the CC0651 binding pocket in the CC0651-hCdc34 structure (cyan) and in the apo-hCdc34 structure (pink). Ribbons representation of (right) the CC0651-hCdc34 complex superimposed on apo-hCdc34. Arrows indicate rigid body movements of secondary structure elements induced by CC0651 binding. (B) Distortion of the active site of hCdc34 induced by CC0651. Structures were superimposed for apo-hCdc34, hCdc34 in complex with CC0651, and Ubc9 in complex with an acceptor substrate RanGap1 (PDB 2GRN) (Yunus and Lima, 2006) . (C) Ribbons representation of the hCdc34-CC0651 structure superimposed on the E2 domain of Ubc1 engaged with donor ubiquitin (PDB 1FXT) (Hamilton et al., 2001 ). See Figure S8 and Figure S11 for associated data. core of hCdc34 and causes compensatory inward movement of helix a1, the a1-b1 linker, and the a3-a4 linker to fill the void not directly occupied by CC0651. The rearrangements in the immediate vicinity of CC0651 occur with virtually no change in the conformation of amino acid side chains and hence represent almost perfect rigid body shifts ( Figure S8A ).
Mechanism of Action of CC0651
The structural alterations wrought by CC0651 could lead to different possible mechanisms of catalytic interference. The most pronounced rearrangement caused by CC0651 is the wholesale shift in helix a2 that causes secondary conformational changes in the active site region of hCdc34. The 3 10 helix that bears the catalytic cysteine residue, which is buttressed against the opposite surface of helix a2 to CC0651, is shifted 2.0 Å relative to the position observed in other apo-E2 structures such as Ubc9 ( Figure 5B ). This movement causes a similar displacement of the catalytic residues Tyr87 and Cys93, whereas the invariant Asn85 of the HPN motif that participates in stabilization of the oxyanion intermediate is shifted to a lesser degree. Notably, in addition to its perturbation of the catalytic center, the binding position of CC0651 on hCdc34 is proximal to a critical E2 surface that noncovalently interacts with the thioester-linked donor ubiquitin to facilitate catalysis ( Figure 5C ) (Hamilton et al., 2001; Saha et al., 2011; Wickliffe et al., 2011) . Finally, CC0651 also causes a minor repositioning of helix a1, which comprises a portion of the E1-and E3-binding sites that are conserved in all E2 enzymes ( Figures S8B and S8C) (Huang et al., 2007; Zheng et al., 2000) . These various structural alterations could, in principle, affect the E1-dependent charging reaction, the E2 catalytic cycle, and/or the E3-mediated interactions with substrates.
To investigate whether E1 binding and the concomitant step of E2ubiquitin thioester formation was adversely affected by CC0651, we performed an E1-mediated ubiquitin charging assay in the presence or absence of CC0651. The inhibitor had little effect on formation of the hCdc34ubiquitin thioester, suggesting that both E1 recognition and the initial catalytic charging step were not perturbed ( Figure 6A ; see Figure S9A for reaction kinetics). Two bioactive inhibitor analogs also did not affect the levels of hCdc34 thioester formation in vivo ( Figure 6B ). We then tested whether the interaction of hCdc34 with the SCF Cdc4 E3 complex was affected by the inhibitor. Consistent with previous results ), hCdc34 could be captured on an SCF Cdc4 resin in a manner dependent on its acidic tail region. The hCdc34-SCF Cdc4 interaction was also not overtly altered by CC0651, both in the presence and absence of Sic1 substrate ( Figure 6C ). The minor perturbations of the helix a1 region thus do not preclude the interaction of hCdc34 with either E1 or E3 enzymes. We then determined the effects of CC0651 on catalytic transfer steps. CC0651 strongly impaired the rate of ubiquitin chain initiation on substrate by SCF Cdc4 (Figure 6D ), as measured by the monoubiquitination of Sic1 by K0 ubiquitin (Petroski and Deshaies, 2003) . In the absence of E3 and substrate, Cdc34 can catalyze the formation of free polyubiquitin chains and also autoubiquitinates itself to form a covalent monoubiquitinated Cdc34 conjugate (Scaglione et al., 2007) . Under these conditions, CC0651 actually potentiated the formation of both ubiquitin dimers and monoubiquitinated hCdc34 ( Figure 6E ), concordant with the observed accumulation of the hCdc34 conjugate in cells treated with the ester derivative of CC0651 ( Figure 4E ). Finally, as described previously (Seol et al., 1999) , purified human Cul1-Rbx1 complex stimulated the assembly of extended polyubiquitin chains by hCdc34, as well as the formation of free di-and triubiquitin, and monoubiquitinated hCdc34 ( Figure 6E ). The addition of CC0651 to this reaction completely inhibited the assembly of polyubiquitin chains and decreased formation of free triubiquitin and, to a lesser extent, hCdc34 monoubiquitin, but had no effect on production of diubiquitin ( Figure 6E ). The fact that Rbx1-Cul1 stimulated some hCdc34 activities, even at a concentration of inhibitor that abolished all traces of substrate ubiquitination ( Figure S5 and Figure S6 ), was consistent with the fact that CC0651 did not appear to inhibit the hCdc34-SCF Cdc4 interaction. The selective effects of CC0651 on the various hCdc34 reaction products suggested that the inhibitor perturbs the ubiquitin transfer reaction in a subtle and potentially substrate-selective fashion.
Given that hCdc34 and SCF Cdc4 were able to interact in the presence of CC0651, we reasoned that the CC0651-hCdc34 complex might exert a dominant-negative effect toward other E2s that might otherwise catalyze SCF-mediated ubiquitination. The closely related enzyme Ube2R2, which is completely resistant to CC0651 ( Figure 2D ), fully supported Sic1 ubiquitination even in the presence of excess Cys93Ala catalytic site and Asn85Ala catalytic transfer mutants of hCdc34 ( Figures 6F, 6G , and 6H). However, in the presence of both hCdc34 and a high concentration of CC0651, Sic1 ubiquitination by Ube2R2 was potently inhibited ( Figure 6F ). Somewhat surprisingly, this dominant-negative inhibitory activity of the CC0651-hCdc34 complex did not depend on thioester formation or on catalytic transfer, as shown by the equivalent dominant-negative effects of the catalytic Cys and Asn mutants, respectively ( Figure 6F-6H ). The dominant-negative effect was, however, greatly attenuated by removal of the acidic tail of hCdc34 required for cullin interaction or by mutation of hCdc34 residues required for CC0651 interaction ( Figures S10A-S10D) . These results reveal a further unexpected feature of CC0651, which can evidently influence the overall SCF ubiquitination reaction beyond its effects on the catalytic transfer activity of hCdc34.
DISCUSSION
Our structural and biochemical analysis demonstrates that CC0651 acts through an allosteric mechanism to inhibit ubiquitin transfer to substrate, without overtly interfering with ubiquitin thioester formation or essential interactions with E1 and E3 enzymes. Rather, our data suggest that CC0651 subverts the catalytic activity of hCdc34 in a complex manner. Though the inhibitor clearly abrogates the initial transfer of ubiquitin to substrate and inhibits the autocatalytic assembly of longer ubiquitin chains, it nevertheless stimulates hCdc34 autoubiquitination and the formation of diubiquitin by free hCdc34. These differential effects of CC0651 suggest that the underlying mechanics for synthesis of each of these products may differ in subtle respects. The dominant-negative effect of the CC0651-hCdc34 complex may depend on the requirement for SCF dimer formation in (100 mM) and E1, ubiquitin, and phospho-Sic1. hCdc34 retained after washing was detected by immunoblot.
catalysis (Tang et al., 2007) and/or dimerization of hCdc34 itself (Gazdoiu et al., 2007) but cannot be simply explained by a catalytically inert complex because mutational inactivation of hCdc34 alone does not yield dominant-negative behavior. The fact that this dominant-negative activity does not require the catalytic ubiquitin thioester suggests that the inhibitor may form a noncovalent ternary complex with hCdc34 and ubiquitin that interferes with the SCF catalytic cycle . Recent evidence indicates that weak noncovalent interactions of ubiquitin with different E2 surfaces are crucial for efficient catalysis. A conserved interaction between the donor ubiquitin and the E2 surface defined by contacts with helices a2, a3, and a4 exposes the thioester linkage of the donor ubiquitin for attack by the incoming acceptor ubiquitin during the chain elongation reaction (Hamilton et al., 2001; Saha et al., 2011; Wickliffe et al., 2011) . In Ube2S, a second weak noncovalent interaction surface helps to orient the acceptor ubiquitin for Lys11-specific attack (Wickliffe et al., 2011) , whereas in UbcH5, yet another distinct ubiquitin contact surface ( Figure S8D ) appears to mediate the assembly of polymers of the UbcH5-ubiquitin conjugate, which may be important for chain elongation (Brzovic et al., 2006) . These noncovalent ubiquitin interaction sites on Cdc34 may be perturbed upon inhibitor binding, although the donor site is evidently not completely incapacitated because diubiquitin conjugates can still form in the presence of inhibitor. This observation contrasts with the effects of donor/acceptor site mutations in Ube2S (Wickliffe et al., 2011) and catalytic asparagine mutations (Wu et al., 2003) , both of which potently abolish diubiquitin synthesis. The further characterization of CC0651 mechanism of action, particularly the structure of CC0651 in complex with hCdc34, ubiquitin, and SCF subunits, will shed new light on the ubiquitin transfer reaction.
The specificity of CC0651 for hCdc34 over other E2 enzymes is quite remarkable given the high degree of structural conservation and similarity of catalytic mechanism across the E2 family (Wenzel et al., 2010) . Our initial SAR analysis suggests that the efficacy and bioavailability of CC0651 may be improved upon by substitution of nonessential moieties. Our results also raise the interesting possibility that analogous specific inhibitors may be designed for other E2 enzymes. Indeed, inspection of other known E2 structures reveals partially preformed pockets in the vicinity of the CC0651-binding region (see Figure S11 ). It is conceivable that the CC0651 pocket represents a general allosteric control site that may respond to physiological ligands that regulate E2 activity (Nakada et al., 2010) .
The UPS hierarchy is, in principle, susceptible to inhibition at each of its different levels of specificity. To date, only the general 26S proteasome inhibitor bortezomib has been approved for use against human cancer (Nalepa et al., 2006) . Intensive efforts are now underway to identify inhibitors of other UPS enzymes (Cohen and Tcherpakov, 2010) . With respect to the CRLs, inhibition of cullin neddylation by MLN4924 also shows promise in preclinical cancer models (Soucy et al., 2009 ). Due to the partial redundancy of CRL-associated E2s, the inhibition of hCdc34 may afford similar, if not greater, specificity than inhibition of CRL neddylation. In terms of potential clinical indications for hCdc34, the enzyme is highly expressed in T cell acute lymphoblastic leukemia (Eliseeva et al., 2001) , and a dominant-negative allele of hCdc34 enhances the efficacy of bortezomib against multiple myeloma (Chauhan et al., 2004) . Recently, hCdc34 has emerged as a critical target of the let-7 microRNA (Legesse-Miller et al., 2009) , which is a tumor suppressor (Bü ssing et al., 2008) . The development of inhibitors that act at each enzymatic step of SCF-dependent catalysis, including inhibitors of specific F box proteins (Aghajan et al., 2010; Orlicky et al., 2010) , should allow the eventual implementation of highly specific combinatorial therapeutics. Our discovery and characterization of CC0651 demonstrates that the E2 enzymatic step in the ubiquitination cascade is specifically susceptible to small-molecule intervention.
EXPERIMENTAL PROCEDURES
Recombinant Protein Production E1, hCdc34, and human Cks1 were expressed in E. coli and purified by affinity tags and size exclusion chromatography. The SCF Skp2 complex was affinity purified from Sf9 cells co-infected with recombinant baculoviruses that expressed GST-Skp2, His-Skp1, His-Cul1, and Rbx1. SCF Fbw7 , SCF bTrCP , p27-Cdk2-cyclin E, FLAG p27-Cdk2-cyclin E, FLAG p27 T187A -Cdk2-cyclin E, and Cdk2-cyclin E complexes were also affinity purified from Sf9 cells co-infected with recombinant baculoviruses. Ubiquitin was labeled with EZ-link Sulfo-NHS-LC-biotin. Phospho-p27
Kip1 was prepared by incubating 0.1 mg/ml Cdk2-cyclin E (1.25 mM) with 0.1 mg/ml (1 mM) p27-Cdk2-cyclin E or FLAG p27-Cdk2-cyclin E at 23 C for 2 hr in kinase buffer (40 mM Tris-HCl [pH7.5], 10 mM MgCl 2 , 1 mM DTT, and 1 mM ATP). Protein aggregation was assessed by light scattering analysis in the presence or absence of 1 mM CC0651 and 0.4 mg/ml protein.
SCF Ubiquitination and Interaction Assays
For small-molecule screens, p27 Kip1 was ubiquitinated in a 15 ml reaction with 40 nM phospho-p27, 40 nM E1, 5 mM E2, 25 nM SCF
Skp2
, 25 nM Cks1, and 27.8 mM biotinylated ubiquitin in 40 mM Tris-HCl [pH 7.5], 5 mM MgCl 2 , 1 mM DTT, and 0.5 mM ATP at 23 C for 3 hr. The reaction was terminated with assay diluent (BD PharMingen), transferred to 384-well protein A plates (Pierce Technology) coated with 62 ng SC528 antibody (Santa Cruz), incubated for 1 hr, and washed six times with 10 mM Tris-HCl [pH 7.6], 0.05% Tween20 prior to addition of 25 ml of 0.4 mg/ml europium streptavidin in HEPES [pH 7.6], 1% BSA, 0.2% Tween20 per well. Plates were incubated for 1 hr, washed, and read for Eu-time-resolved fluorescence after addition of 25 ml enhancement solution (Perkin Elmer). For gel-based ubiquitination assays, CC0651 and its analogs were preincubated at the indicated concentrations with 0.5 mg E1, 1-4 mg hCdc34, and 50 ng SCF See Figure S9 and Figure S10 for associated data.
phosphopeptide [KKERLLDDHDpSGLDpSMKDEE] , or 50 ng p27 Kip1 phosphorylated by cyclin E-Cdk2), incubated at 30 C for 1-3 hr, and products visualized by immunoblot (Tang et al., 2007) . For E2 charging reactions, 0.1 mg E1, 5 mg hCdc34, 25 mg ubiquitin, and indicated amounts of CC0651 were preincubated for 15 min at 23 C in 25 ml reaction buffer (50 mM HEPES [pH 7.5], 100 mM NaCl) and then initiated with 2 mM ATP at 30 C, terminated by loading buffer with or without 5 mM DTT, and visualized by SDS-PAGE and Coomassie blue. For the Cdc34-SCF Cdc4 interaction, 250 ng of SCF Cdc4-FLAG or FLAGSkp1 immobilized on anti-FLAG M2 resin (Sigma) was incubated with 4 mg of His-Cdc34 or Cdc34 Dtail in the presence or absence of 100 mM CC0651, 50 ng phospho-Sic1 substrate, and/or 0.5 mg E1, washed, and visualized by anti-Cdc34 immunoblot.
Cell Culture Analysis PC-3 and HCT116 cell lines were grown in DMEM supplemented with penicillin/streptomycin, 2 mM glutamine, and 10% fetal bovine serum (FBS , and nontarget control were used as described (Voisin et al., 2008) . For proliferation assays, PC-3 cultures were seeded at 5000 cells/well in quadruplicate in 24-well plates, grown for 24 hr, and then infected with lentiviral supernatant. For small-molecule inhibition, cells were seeded in quadruplicate at 500 cells/well in 96-well plates, grown for 24 hr, and treated with compound. Proliferation was measured by MTT assay (Voisin et al., 2008) . PC-3 or HCT 116 cultures were synchronized in G0/G1 by serum starvation for 30 hr and then released by addition of 10% serum. For epistasis experiments, PC-3 cells were infected with CDC34 shRNA for 24 hr, followed by addition of inhibitor and assessment of proliferation after 4 days. AntiCdc34 (17/CDC34BD Transduction Laboratories), anti-p27 (610242 BD Transduction Laboratories), anti-a-tubulin (DM1A Sigma), anti-ubiquitin (MMS-257P Covance), and anti-cyclin E (Wang et al., 1999 ) antibodies were used as described (Servant et al., 2000) .
X-Ray Structure Determination
Crystals of apo-hCdc34 D184 at 42 mg/ml in 20 mM Tris-HCl (pH 8.0), 0.15 M NaCl, 5% glycerol, and 2 mM DTT were grown in hanging drops by mixing 2 ml protein solution with 2 ml well solution (28% PEG 4000, 0.1 M Tris-HCl, pH 8.5, 0.2 M MgCl 2 , 1 mM DTT, and 7.5 mM glycyl-glycyl-glycine) at 21 C.
Crystals of the CC0651-hCdc34 D184 complex were grown in well solution containing 100 mM imidazole (pH 8.0), 200 mM NaCl, 0.5 M NaH 2 PO 4 , and 1.6 M K 2 HPO 4 . For cryoprotection, crystals were soaked in well solution supplemented with 25% ethylene glycol. Diffraction data sets were collected at IMCA-CAT 17-ID-B and NE-CAT 24-ID-E (APS, Chicago, IL), respectively, and processed with HKL2000 (Otwinowski and Minor, 1997) . Molecular replacement was performed using MolRep (Vagin and Teplyakov, 2010) using the crystal structure of UbcH7 (PDB: 1FBV) or apo hCdc34 as a search model (Zheng et al., 2000) . Atomic models were rebuilt using COOT (Emsley and Cowtan, 2004) and refined using Refmac (Murshudov et al., 1997) .
ACCESSION NUMBERS
The Cdc34 and Cdc34-CC0651 complex structures have been deposited in the Protein Data Bank under ID codes 2ob4 and 3rz3, respectively.
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